00:00 , Aug 6, 2013 |  BC Extra  |  Politics & Policy

San Diego's Roth passes away

Duane Roth, a founding member of the executive committee of Biocom, a trade association representing life sciences companies in southern California, passed away on Aug. 3 from injuries sustained in a bicycling accident on July...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

Optison regulatory update

FDA added a boxed warning to the label of Optison to state that serious cardiopulmonary reactions, including fatalities, have occurred within 30 minutes following perflutren-containing microsphere administration. The ultrasound contrast agent, which consists of perfluoropentane-filled...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders, Biogen Idec (BIIB) said it had not received any definitive offers and would remain independent. The announcement came after market close on Wednesday and BIIB plunged $17.97 (24%) to $57.91...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase IIb discontinued

ALLP discontinued a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients in order to focus on developing Oxygent in China. Beijing Double-Crane Pharmaceutical Co. Ltd. (Beijing, China), which has Chinese rights to Oxygent,...
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase IIb started

ALLP began a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients undergoing primary coronary artery bypass graft (CABG) surgery under cardiopulmonary bypass (CPB). The trial will compare 1.5, 3 and 4.5 mL/kg of...
07:00 , Apr 9, 2007 |  BioCentury  |  Tools & Techniques

O, what a simple solution

Blood substitutes have been a black hole for biotech companies. There are no such products approved by FDA or EMEA after nearly two decades of effort. Nevertheless, candidates that attempt to replace the oxygen-carrying ability...
08:00 , Jan 1, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II start

This quarter, ALLP will begin a French Phase II trial to prevent POI resulting from hypoxia during major surgery. Alliance Pharmaceutical Corp. (ALLP), San Diego, Calif.   Product: Oxygent perflubron   Business: Gastrointestinal   Molecular...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II delayed

ALLP said the German Ethics Committee rejected an appeal to start a 65-patient Phase II trial to prevent POI resulting from hypoxia during major surgery. In August, the committee voted against the trial protocol. ALLP...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II ongoing

The German Ethics Committee voted against letting ALLP start a 65-patient Phase II trial to prevent POI resulting from hypoxia during major surgery. ALLP said it will appeal the decision and hopes to start the...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Company News

California Institute for Regenerative Medicine board of directors update

California Institute for Regenerative Medicine (CIRM), San Francisco, Calif.   Business: Other   Appointed: Duane Roth, chairman and CEO of Alliance Pharmaceutical Corp., to CIRM's oversight committee; he replaces Gayle Wilson, who resigned in January...